ࡱ> @= Vмp5@ grA0` v<R xZolwgGaNKL3Ď8p+DžИʜ1BKZ"B#D1|)ri|@*7TBMZTBJej(Em$7w>̛͛7̛][BL #ROfW PVP(:3by ~J?@EBV.>Dq3LT ΏtJGcrex,ÝH'mFjp @lNC - )4?]wܭ,cU^a(*+& Uno0:BJ^z%1цqnUWUW҃_.} ɅJ/j5' 5#„uKD }-Co47y5˼ a:1?P܆04RjkZ{ʫ!?kߣ5~sw/(m#L:|BM}~GoBЇCrxm kF}z޴IچNuB]ug⺾P]H&[:^3oXE aQ5֓=&q K~?t骂?%W-JANfo8_$lDyږmZɿ/q^?|&f[V+op^k9I7^xڢb¿y|)f۬V -%j}fgsl}h9cs@ρf}>+>+>+Ensp\Ϲ2^R!m^g@8(03)l4 Sd0MjݦnAY7VH\lZ M oCoH]H_n=b.=h?]UWv%p$+F]#.ouRys8Bco:_K5~ƿ5!?kߣab4#ߞA?}O '*??+ 'BƗ㓾G{g\=Pd_EK061t(^{'']Q|⡦Q*CLk #{H%#Q{A%]~}@iOzOx7bpz-4wxZyب"+-'H4sȊ˷&x;pe;lFŲh[oe!mN 8_iYg狙W^ C<%-C;]9ӝtE@G"reHzu%Od&0b̸ C>0̵܇ɘ`V"J CCz{q{Em>p{ȸ.pN'swx ~L?'&s_vW\0/|P_;ݎ tLڋ۽sy7|bViOv .7f4yй=ǛY@ھc1t }yĎn =_$C!s򛵛άo =@2iҞ{)eOŹ )kNEyg)=yϴ}_'&|zW E_1֚E>6"b +Gu~qd)-~E>a1 Q#}L`̊R}z7~p]j3#dO ҿ>mOTSSq\u5.֪.a´[D4zwX# Q~&9bGACʝ`4\1n,![[OP 6g*~Ӹ' yGW C~;~*띠w -٢)]$p 4*[3x̼,J=RY8&*C[uWL(ߨ&TL:-gBVN ^k&UW8tuǮS砰 nӥ'>]3ͷ"o"o*j, k/{URn6]pO~ܥ$[~bsxx:gO.QV~}:5 ) u~NLmn`a#MHmAvZwm4-XF],rvX_FGhU/EjI#Rw>2R<d]~s,Kbe gS۔Hy }3_C.#o7.lk2s'9-l[e>2^ƤZ3̵ ܆yW[7[jT삣糝/u,܇|]ggM~NޮSZH ~5x%δi5=*+_#@=Gfo,%Z{/Td8##x[lTUp] -Eh cWRHUA!1&6BJ 5sID%bLTj|Qgӝ{ڲ9̙9sf3gZB!m ģHX|i'hFW89 " !ꋀZعVyH wFc`vӑgzMc|^h;|[h# ik\ʖ!}-xp)wqݦfx9cȱrs K4k n|f3=gzq_^7UL}gd+Ǘ\~z0p{___"z,!3Gk"zy?M~ЎB؍YA;X:amt3z譝LbX4ģGR.O+|ZMS bu'z2d2y>-}K#~|T{\~:6cl@i}̓@Kaڬ9{n;">錐.!^Ut5Y'/t;?YXowÕKx|GS.,e]"-sY $",\Zjߴq<2Q.R§M>U>joέgGڜ]o]#!˫a/JHmLD>H+8N#IqڲfP{A=4;s2幢{ы@f)-5OH:fyp[hSnRy"$cC+S3NNc>-23JubƯt2 uP?,;Y'VDzѩÿJ u GY')0(8葉Roϲbeѱe)ePƲt2IO>ebu7X|yʵ\,{j.ݍen,[mbYOIJ:DahY?ނ"Ph&>RdX{Wܜ$=M6fxv؎fC$&X^Y&H0Qy&|pTNm4|#"5/S We+8WnqR#aw(=BuX gi_Bx ܳFY9Yq8y<8 g ;ipv:4D|;< ŷo+5zys|B[J;+ b,cW!sgE"']UAJ|*|+|y+uNo|"'*Ax +1YĄ~ b$yfd9jerNy7Dg| w .Q`70 />ރ⬷mޣFβWBg{ [p*\1gИ\YzY!찉*9;\RY2f,,KlIؖw'j\MZx?K0.cB6U=lcpmhl]Vϵ ce>S%2s_(}k|Rԇh]aKڻ>g{] 6v ]y1Z̐)ȶtMnElc?'u,a캚m]Wk ؞ Ω&co7z}c ÷Q+|N*$3?ʹVo Ѯ76y) :u.g[|>"E,e@=yu 3~s`>Td8##Gx[klTE{`ERCŶP_`IX RWbib4"%$Dd1QQ`j1A ~3{;{wڲս0w9sxBw' Q4o|!t&"5%g\9` }`7Ax8@*Ⱦ/joq+ v@'WT_W"nIޓ=H ~8z}nz^m4g>^GruO0ҵ#n|&=@IfcL/SOxߔߔ+ٙ0  2D&$}y?'atЄ(ޣnk[Bor.ZoRIfBY~"3F8x2|+73|370|W2|e?͌;SoNǓm$IiӷٙUӗ~oZ!kA#-zZvteڟ7|6xV[5h jPC|g8,^r)){IM_>ol'DaPD~U: $u:.t"X ]Q_?9#tr^N\~O'y'(wNmD >4uR)d{NJoI(WՇN}s~:Y~[PHE!E(#PLIyls>5v+v[契"᧟$;^bjKszHO{9v?^X)qϱ>°@߬gi4Xy<Չ]|h M/=o*_.6 ס\.ρ7ǿF׊U "p<ЇI/atݥ2DyF[!Fge,Oas׸sXF.CSy$0*MYog,AZmJSt~<X9)Vx#GQx4\'Y;vkUȉ|s=4*E*kUY-NRNn#ޟHiT;e8czv;[͵ƽCoU=l l CsRok<-q{ ׇP{갰?!{e8"{u+k;D)>a}FîeFav@EQ:4ٯö-m+oܶ}9_'fmg(6uV\8k:E`c)dbiYڹϔ϶5dmgdKR-k$+|U?߶[TU|$c`t?;&Pg$Maˉj@=ݔsjpvz \x]}ۻ=a½YIxe$(rW\rF b,=@XD)P"&*/)Vi HΏ$TUď{3{ogzv{3z^~{o^OqrH!@:fg?dvsl͌eej%p_g4w#0, q(<x .4_=)† v}xr<Al] 6akߕpVCZv Vyܟ`# E'y{/R\}.;h8FbF*-͞|o^saUe u}O$e[&tJc_Gtbht_/[~-߽>War2Pt042 2<PL~zkdLdx*X:"n'2,42\eꡫ+Vxr DA ; C*]42&OC* J ; yq;hdx07aFLK_W|9ߩ_cnjcg:`?!?y!}]Q;gprT:i 7!?7R `q2ſaWP(Mis 9oJ}W]Q:0#0;J! V(8A4fE޶~b[%¯U@[RQ.d@c~8q)#f<;I#Sr=[rBeTuϯ3bz^A!~P~ϵ Կh+f ɣ,~+Iz;Sz]/hvf^OR~oѫ~o7Ĝ$oS m˃^C?łUȵ=lΟvr8lyMY6_}Y_*QiQ4-P''f;WƖy}YP5/~slgmGm{TZU~S\ϯ׉sj֣ ﹘_ ӿh7rwYGJYMCSk=Do':)-uf`sF)?L`˸k38VNsm8o;;]</ѶWhq͊'iX,c3\lgumm\u.>v>,Ѷ48Kit:i=SmS*&^ˬ7=D;.t$[o:!z :B=ORI;4V:woRVbgl`t"1T-}Q">0M|F*z(n~?=փ^C1ڏP4/4V+eYosSAo ޿"_m#i.KZ&:9_(jH'$mv&Ik%/eųZwqSuJVyƪDCW.r2{SCn=wre KղPsCQT˾B1iFF-NfApվ4?|b]+a eُ|IsHqcq!O1;hC'!^~c#|ccsMol MO!ˉb/}5spGˌaOs0ccLy$>~b[ ;ZƓk󪽧nNOZķ:ƽ-.s]R>Hby8ϲX0Q-":Rj4aol|}[E:-Cއ#LQ *[ W3x<C;X?llW{o9X& i'ť&jK \]`V?N2ԮƲHʞxU']_e?:7xcd?{ߘ-}!<Lɾ2Y=Tv.VFފvnIJ 2ffM1}˧]ܫh/}Χ t82t=ۅn6jIdڂn9wy[=q@ߊL6ęϯ%tS#k8"\]ŖkJ#(Pjt˯Ð9Oюi)xDq4иL\[Hn"w` %l+c0M2-H6#~2Vob&S]1bC S[nAtK<-눦MaǬƤϽ <~> ~0VM 7Xn0|1!g~ob{keO:<wH© W'j cL7ӑoCL#^nB;tc,鴧2鉜r3Q&`k4[k8x3a1:OAvIw!( 5*N>clfg (lsx+Z,ڰar)`y-m˃loP}'!LtEǶw$~oo9)n9'F~pD%_ 1?7*^_Wlnx?3F{]{ vh9[+ܶ&xsk>2;Pm}W͗=>~=/P;ӆ=hNnB=x3l^mnyUo~Yb&l{˷ ;o3s m OU@Ya}W~YՇ=M{ 0YMֽ{i^l=4%:YׯO=O{eg2.M7([G|F$ߎ\ھuuLc~'|a%%ϳ80E9w ņWEQS8 RJwZ_2?Vn_/jwg,?S8-iiDc/I㄁@ X'i2Xr_u2@4Z42&`@>z{Mc`6)XC'ۜX$PۡVҜ%ce~RY)yxT΁H1 ױ؋wW{(JL$u*ԾiEq,}~9vE׭J؍ֵPc{*j4LGyOwݓ+qT@(~<5rⅿ'SSz8%_M { ֌^JC4-.2k+͓8% />?c gcKu;R/=}2%Af 5}-7%7y~BSI_`4ϰ7>؃ׂj4Ht+L=} J<ؽd,]u~C:OT>"@M>}Ĵ}x!g"{!Qe#XEبS\>/_\b)|Pٮ a?VGal{ZWjE wԘG Wrֵ iTc~xΦ|u<u]r=, D;pu]\)OV'&*ewcշv}NDy~;})51j1s,bF[1΋͟ |O|W7̗bzZ%_O'c- {3Y~+}7z_+}RwfJ;1~MgUb|g^B5A_oabti%<֗v/v'>m&l 1NΣߞB-E6pO0{;Ӎܻez,{%wJIPq׻N,;0?TV/xN}6 H81oP,(  * @V Chart Excel.Chart.80*Microsoft Excel Chart3s Chart Excel.Chart.80*Microsoft Excel Chart&} Chart MSGraph.Chart.80*Microsoft Graph Chart'~ Chart MSGraph.Chart.80*Microsoft Graph Chart6 Chart Excel.Chart.80*Microsoft Excel Chart`/ 0DTimes New Romanll-a0DArialNew Romanll-a0@ .  @n?" dd@  @@`` d\#    '*  # & B+ 0b7p = ngO*7O P RVW#ZegR3dTcngX%hi n orr}e   4"$Vмp5@ grA "$fo,%Z{O "$u 3~s$"$ݔsj\$"$0^TfbB/ a* 0AA@3b ʚ;t8s8ʚ;g42d2d2 -a0@fppp@ <4dd8))0l<4dddd8))0l <4KdKd8K*0lj0___PPT10 *___PPT9 z? %CNeoPhe in the Treatment of Phenylketonuria New Formulation of LNAA.D,((62nd Ukraine Congress On Clinical Genetics October 2005<7$ $'$ ZUSA Reuben Matalon, M.D., Ph.D. Kim Matalon Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Ukraine Elena Grechaninab*$f Large Neutral Amino Acids (LNAA)!!bPhenylalanine (Phe) Leucine Tyrosine Tryptophan Methionine Histidine Isoleucine Valine Threonine 0bZZbTransport of LNAA to the Brain$( (Phenylalanine (Phe) 0.12 0.45 Leucine 0.15 0.53 Tyrosine 0.16 0.58 Tryptophan 0.19 0.71 Methionine 0.19 0.77 Histidine 0.28 1.10 Isoleucine 0.33 1.30 Valine 0.63 2.50 Threonine 0.73 3.00Z[Andersen AE, Avinsl ( LNAA injected to rat pups Phenylalanine hydroxylase was ihibited by parachlorophenylalanine Brain phenylalanine decreased 1976 Arch Neurology 33:684 (||>( > Tyrosine in The Treatment of PKU!! Lou et al used Tyr 160 mg/kg in treated patients with PKU Increased attention span Increased dopamine synthesis 1987 Acta Paediatr Scand 76:560 8;6"r!wTyrosine in Treatment of PKU Pietz et al. used high dose tyrosine in adults with PKU and high blood Phe No difference in treated group vs placebo 1995 J Pediatr 127:936 4yy Tryptophan in Treated PKU Nielsen et al used tryptophan 4.5 gm/day to treated PKU for 3 weeks Showed a 3 fold increase in 5-HIAA in CSF despite high blood Phe 1988 Dietary Phenylalanine and Brain Function. Birkhauser 8Z=Z: LNAA Supplementation in PKU Dotremont et al. used LNAA and a low protein diet 0.6 gm/kg on 4 patients with PKU After 1 month subjects found with negative nitrogen balance Lysine was limiting amino acid 1995 J Inherit Metab Dis 18:1270Z!Z  PreKUnil Composition per Tablet Tyrosine 191 mg Tryptophan 65 mg Arginine 35 mg Leucine 35 mg Isoleucine 35 mg Valine 35 mg Methionine 35 mg Threonine 35 mg Lysine 0 mg P# G.8Km (app)  Km (1 + "[aa]/Km]   This predicts that, if the plasma level of an LNAA is much less than its value of Km, then that amino acid will not compete effectively for the carrier proteinJ1E,Neo PheL-Tyrosine 195.0 mg L-Tryptophan 51.0 mg L-Methionine 32.0 mg L-Isolecine 35.0 mg L-Threonine 32.0 mg L-Valine 35.0 mg L-Leucine 130.0 mg L-Histidine 30.0 mg L-Lysine 30.0 mg L-Arginine 30.0 mg  P-LNAA Transport in Intestinal Mucosa Km mmol/L*.%Phenylalanine 1.0 Leucine 2.0 Valine 3.0 Methionine 5.0 Histidine 6.0 Competition effect is not likely to occur in tissue other than brain unless high concentration of amino acids is used 8ZZRuK20Hidalgo Biochem Biophys. Acta 1008: 5-30a (1990)11`?PPKU Mice on NeoPhe Control phe mg/dl NeoPhe:Q@Y9_DDenmark LNAA STUDY$kIDenmark LNAA STUDYmJ Russia LNAA STUDY (nK Russia LNAA Study (oLUSA LNAA STUDY(pMUSA LNAA STUDY\tOS5:US Blood Phe and Tyr NeoPhe Patient K 1 Week mol/L (mg)";/ " T6.US Blood Phe and Tyr NeoPhe Patient G 1 Week// |UNeoPhe 0.5 g/kg in PKU Subjects (13 subjects Mean age 26.6 years 7 males, 6 females Mean decrease in blood Phe after one week 243 mol/L Average decrease in blood Phe 22 %.b+ ,J6VNeoPhe 1.0 g/kg in PKU Subjects (7 subjects Mean age 25.2 years 5 males, 2 females Mean decrease in blood Phe after one week 377 mol/L Average decrease in blood Phe 25 %.a+ ,I6WDFigure 1. Blood Phe Response to 0.5g/kg NeoPhe in Patients with PKU*E@$ $$YEFigure 2. Blood Phe Response to 1.0 g/kg NeoPhe in Patients with PKU*FA$ $$wR CONCLUSIONSFor the first time mixture of LNAA can lower blood phenylalanine Using NeoPhe avoids lysine deficiency Lysine deficiency can lead to negative nitrogen balance and decreased levels of carnitine xSAcknowledgementParticipants in the study Professor Elena Grechanina Kharkiv, Ukraine Professor Peter Novikov Moscow, Russia Dr. Jytte Bieber Nielsen Glostrup, Denmark $PC  0` ` ̙33` 333MMM` ff3333f` f` f` 3>?" dd@,|?" dd@   " @ ` n?" dd@   @@``PR    @ ` ` p>> }u (  +  6@V P  yFuture Role of Large Neutral Amino Acids in the Transport of Phenylalanine into the BrainClick to edit Master title stylez z  0Z   RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  0 ``  X*  0H `   Z*  0 `   Z*H  0޽h ? Default Design 0(  0 0 0 P    X*  0 0     Z*  0 6 `P   X*  0 6 `   Z* H 0 0޽h ? ̙3380___PPT10.A1Єm0 0$(  r  S )   r  S \c `    H  0޽h ? ̙33y___PPT10Y+D=' = @B + 0  (  r  S P   H  0޽h ? ___PPT10i.G@D_+D=' = @B +m 0 @$(  r  S    r  S  @  H  0޽h ? y___PPT10Y+D=' = @B +G 0 nfP(  r  S `&y  y r  S 'y @ y   0@(y  Km mmol/L Km app` 2   0/y@ zBPardridge, Inborn Errors of Metabolism in Humans. MTP Press, 1980.C 2CH  0޽h ? y___PPT10Y+D=' = @B +0 0 0 0(  x  c $P   x  c $  H  0޽h ? 80___PPT10.I=vm 0 `$(  r  S gP   r  S   H  0޽h ? y___PPT10Y+D=' = @B +m 0 p $(   r  S CP   r  S D  H  0޽h ? y___PPT10Y+D=' = @B +m 0 $$(  $r $ S TJP   r $ S   H $ 0޽h ? y___PPT10Y+D=' = @B +m 0 4$(  4r 4 S xP   r 4 S   H 4 0޽h ? y___PPT10Y+D=' = @B + 0 <4@(  @r @ S yP  y r @ S _y y  @ 0Fy   @ 2 H @ 0޽h ? y___PPT10Y+D=' = @B +} 0 $(  r  S yP  y r  S y y H  0޽h ? ___PPT10i.E1+D=' = @B +<0  <<\a;(  b; p a #"NBp: Y <p?p zAbsolute and apparent Km values of neutral amino acids for the neutral amino acid transporter in the BBB (Partridge, 1980){{ @`  <p? p L0.40 @`  <zp?   L0.09 @`  <p?0  L0.10 @`  <$p?0 KArg @`  < p? p L0.25 @`  <x9p?   L0.10 @`  <hp?0  L0.30 @`  < B}?  J23.6*(" ? B0}?  J23.9*(" @ B}?  J23.6*(" A B}?   VAvg each time pt*(" B Bt} ?"`'   J10.9*(" C BX}?'   B(  D B}? '   J24.4*(" E BL}? '  J24.2*(" F B}? '  J21.7*(" G B$?'  J21.6*(" H Bz?'   KF 588*(" I BL ?"`T '  J13.5*(" J B?T '  B(  K B(? T '  J21.9*(" L B}? T '  J21.2*(" M B? T '  J25.7*(" N Bp?T '  J23.2*(" O B0?T '  LF 586**(" P B ?"` T  I8.5*(" Q B4? T  B(  R B? T  J19.8*(" S Bh? T  J24.4*(" T B? T  J21.7*(" U B? T  J20.6*(" V Bp? T  KF 585*(" W B ?"`   I7.8*(" X Bt?   B(  Y B?   J30.7*(" Z B?  J25.3*(" [ B0?  H30*(" \ B?  J23.8*(" ] B?   KF 584*(" ^ B0 ?"`   J10.3*(" _ B1?  B(  ` B5?   J20.9*(" a B`9?   J22.2*(" b B+ UP  L1164 @` \ <ߚ?`+ >P  ^ 04 @` [ <? +  L1525 @` Z <? +  L1602 @` Y <l$j?  +  L1480 @` X <zj?j  +  L1591 @` W <(j?U j +  L1691 @` V <̍j?> U+  L1262 @` U <ԏj?` >+  ^ 02 @` T <j?  L1608 @` S <0j?  L1627 @` R <\j?   L1597 @` Q <j?j    L1697 @` P <(j?Uj   L1681 @` O <Htj?>U  L1436 @` N <j?`>  X1 tablet/kg 01 @` M <8j? OAverage @` L <Xj? OPKU 128 @` K <j?  OPKU 105 @` J <j?j   NPKU 93 @` I <?Uj  NPKU 39 @` H <0 ?>U NPKU 20 @` G < ?`> U Blood Samples @``B  0o ?`>`B  0o ?`P >P `B  0o ?```B  0o ?`B  0o ?>U`B  0o ?`` `B  0o ?Uj `B  0o ?j  `B  0o ? `B  0o ?`B  0o ?`B  0o ? `B  0o ?` `+ `B  0o ? + `B  0o ?`+ `P `B  0o ?+ P `B  0o ?>P UP `B  0o ?UP j P `B  0o ?j P P `B  0o ? P P `B  0o ?P P `B  0o ?P P H  0޽h ? 33___PPT10i.p+k+D=' }= @B +10 0 //G1/(  r  S 0jP  j .x   #"*  <@ ?"` L1448 @`  <9 ?"` L1359 @`  <B ?"`  L1413 @`  <xL ?"`   L1477 @`  <U ?"`  L1739 @`  <^ ?"` L1252 @`  <(h ?"` W2 tablets/kg 08 @`  <Xb ?"`@ L1332 @`  <y ?"`@ L1373 @`  <p ?"` @ L1233 @` ~ <t ?"`  @ L1370 @` | <L ?"` @ L1537 @` z <ܝ ?"`@ L1146 @` x < ?"`@ ] 09 @` v < ?"`@  L1311 @` t <4 ?"`@  L1313 @` r < ?"` @  L1179 @` p <8 ?"` @  L1389 @` n < ?"`@  L1556 @` l <L ?"`@  L1119 @` j < ?"`@  ] 11 @` h <$ ?"`   L1351 @` f < ?"`   L1335 @` d <- ?"`   L1222 @` b <@ ?"`  L1349 @` ` <- ?"`  L1650 @` ^ <@- ?"`   L1199 @` \ < - ?"`   ] 15 @` Z <0- ?"` P  K160 @` X <t:- ?"` P  K268 @` V <+- ?"` P  K184 @` T < L- ?"` P  K220 @` R <U- ?"` P  K-58 @` P <(G- ?"` P  K184 @` N <Lh- ?"` P  ]Decrease after 1 week @` L <p- ?"`P  K257 @` J <y- ?"`P  K292 @` H <d- ?"` P  K375 @` F <t- ?"` P  K348 @` D <- ?"`P  J31 @` B <- ?"`P  K237 @` @ <- ?"`P  ]Decrease after 2 week @``B 0 0o ?`B 6 0o ?`B 7 0o ?`B > 0o ?`B  0o ?`B  0o ?@`B  0o ? `B  0o ?  `B  0o ? `B  0o ?`B  0o ?`B  0o ?@`B  0o ?@ `B  0o ?@ `B  0o ? `B  0o ?  `B  0o ? P `B  0o ? P `B  0o ?P `B  0o ?P `B  0o ?`B  0o ? `B  0o ?  `B  0o ? `B  0o ?`B  0o ?H  0޽h ? 80___PPT10..0G 0 DG   E <-?0RP QTyr  E <X-?j 0P R  @` E <-?0j P >   E <-?%0P c Phe   E <-?0%P >   D < -?R{  F1.97& " D <-?R{  G108.3& " D <-?j {  R  @` D <-?j {  F6.27& " D <_?%{  G376.2& " D <h-?%{  H3 days& " D <L-?R F1.88& " D <-?R G103.4& " D <2?j  R  @` D <<2?j  F8.72& " D <-?% G523.2& " D < 2?% H3 days& " D <2?R F1.66& " D <$2?R F91.3& " D <#2?j  R  @`  D <%2?j  G11.14& "  D <H)2?% G668.4& "  D <-2?% H3 days& "  D <12?R F0.98& "  D <H62?R F53.9& " D <A2?j  R  @` D <C2?j  G11.98& " D <xG2?% G718.8& " D <K2?% F0 & " D < P2?RP Gmg/dl& " D <xT2?PR Hmol/l& " D <$`2?j P R  @` D <b2?Pj  Gmg/dl& " D <e2?%P Hmol/l& "/ # <j2?P%RJB___PPT9$ aKA Time>  " "ZB D s *1 ?0%0`B D 0 ?{ %{ `B D 0 ?0`B  D 0 ?0ZB E s *1 ?%00`B E 0 ?ZB E s *1 ?0j 0ZB E s *1 ?j 00ZB E s *1 ?0R0ZB E s *1 ?R00`B E 0 ?`B E 0 ?`B E 0 ?`B E 0 ?`B E 0 ?`B E 0 ?{ `B E 0 ?{ `B E 0 ?%{ { `B E 0 ?{ j { `B E 0 ?j { { `B E 0 ?{ R{ `B E 0 ?R{ {  D Bhw2$g : =t `  E #"&k`  D <z2?R  F1.52& " D <~2? R F83.6& " D <2?j  R  @` D <2? j  F9.76& " D <2?%  G585.6& " D <2? % H3 days& " D <H2?R   F2.91& " D <2? R  G159.5& " D <L2?j   R  @` D <,2? j  F9.54& " D <Э2?%   G572.4& " D < 2? %  H3 days& " D <x2?R   F2.30& " D <к2? R  G126.5& " D <(2?j   R  @` D <2? j  G10.12& " D <2?%   G607.2& " D <2? %  H3 days& " D <2?R   F0.78& " D <2? R  F42.9& " D <2?j   R  @` D <2? j  G11.79& " D <h2?%   G707.4& " D <P2? %  F0 & " D <2?R`   Gmg/dl& " D <2?` R  Hmol/l& " D <t?j `   R  @` D <t?` j  Gmg/dl& " D < t?%`   Hmol/l& "/ D <t?` % RJB___PPT9$ aKN Time>  " "HB D C ` %` HB D C %HB D C ` HB D C `  `B D 0 ?` j ` HB D C ` R` `B E 0 ?j HB E C RHB E C %` ` HB E C  `B E 0 ?j ` ` HB E C R` ` HB E C   HB E C  HB E C   HB E C  HB E C   HB E C  HB E C  HB E C %`B E 0 ?j HB E C Rr E S t`   t H   0޽h ? 80___PPT10.5) 0 ((7dH((  Hr   " " @`HB ,H C HB -H C HB .H C HB /H C   `B 0H 0 ? HB 4H C  `B :H 0 ? HB ;H C  `B >H 0 ? `B TH 0 ? H H 0޽h ? 80___PPT10.8ID 0 CC0k]C(  \r \ S u0  u  \ Bud   t u  ] #"&PPu  ] <u?*0 T   @` ] <0u?*0 gTyr  @` ] <su?Q 0 R  @` ] <u?Q 0 T   @` ] <v?0 u Phe   @` ] <8 v?0 T   @` 6\ <v?* u  \2.55& " @` 5\ <#v? *u  ^140.25& " @` 4\ < ,v?Q u  R  @` 3\ <@5v? Q u  \1.93& " @` 2\ </v? u  ]115.8& " @` 1\ <Iv? u  ^4 days& " @` 0\ <Sv?*  \1.34& " @` /\ <\v?*  \73.7& " @` .\ <xev?Q   R  @` -\ <dov?Q  ]19.97& " @` ,\ <,jv?  ^1198.2& " @` +\ <`v?  ^2 days& " @` *\ <v?* \1.27& " @` )\ <v?* \69.8& " @` (\ <ؠv?Q  R  @` '\ <tv?Q  ]21.51& " @` &\ <  " " @`HB 7\ C HB 8\ C u u HB 9\ C HB :\ C `B <\ 0 ?Q HB A\ C *`B S\ 0 ?u Q u HB X\ C u *u HB l\ C HB m\ C `B n\ 0 ?Q HB q\ C *HB s\ C HB t\ C  HB y\ C  HB z\ C  u HB \ C  u HB \ C u u `B \ 0 ?Q u u HB \ C *u u f!t   ] #"&   \ <( w?R \3.77& " @` \ <w?R ^207.35& " @` \ <\w?j  R  @` \ <l(w?j  ]26.81& " @` \ <H2w?% ^1608.6& " @` \ <L  " " @`HB \ C  % HB \ C %HB \ C   HB \ C   `B \ 0 ? j HB \ C  R `B \ 0 ?j HB \ C RHB \ C %  HB \ C  `B \ 0 ?j  HB \ C R  HB \ C   HB \ C  HB \ C   HB \ C  HB ] C  HB ] C HB ] C HB  ] C %`B  ] 0 ?j HB  ] C RH \ 0޽h ? 80___PPT10.<Bz/ 0 .{.PRd.(  dr d S +x  x  `  d #""`  x d <|x?`? >   d <x?m? 7Try  d <Rx?O m? R  @` d <8Vx?O ? >   d <Yx?]? _ Phe   d <tw?]? >   )d <`x? `  F2.12& " (d <Pcx?m   G121.5& " 'd <xox?O m  R  @` &d <Xqx? O  G12.79& " %d <dux?]   G767.4& " $d <Lyx? ]  J4-7 days&  " #d <}x?`  F0.58& " "d <px?m  F31.9& " !d <ȍx?O m  R  @`  d <x?O  G22.93& " d <x?]  H1375.8& " d <Xx?]  F0 & " d <x??` Gmg/dl& " d <px?m? Hmol/l& " d <x?O ?m R  @` d <x??O  Gmg/dl& " d <x?]? Hmol/l& " d <x??] IES Time& "HB *d C ]HB +d C  ] HB ,d C HB -d C ```B /d 0 ?O HB 4d C m`B ?d 0 ? O HB Dd C m  HB d C ]HB d C  `B d 0 ?O mHB d C `HB d C `` HB d C  HB d C ` ` HB d C ]  `B d 0 ?O m HB d C  ` d @  d #"```@  x od <x?3 F2.84& " nd <x?3 G156.2& " md <Hx? 3 R  @` ld <(x?3  G13.81& " kd <x?%3 G828.6& " jd <x?3% H2 days& " id <lx? 3 F1.07& " hd <x? 3 F58.8& " gd <px? 3 R  @` fd <Px?  3 G16.09& " ed <x?% 3 G965.4& " dd <Dx? %3 F0 & " cd <\z?@   Gmg/dl& " bd <z?@   Hmol/l& " ad <z? @   R  @` `d <z?@   Gmg/dl& " _d <z?%@   Hmol/l& " ^d <<z?@ %  IRC Time& "HB pd C @ %@ HB qd C %HB rd C @ HB sd C @  `B ud 0 ?@  @ HB zd C @ @ `B d 0 ? HB d C HB d C %@ @ HB d C  3`B d 0 ? @ @ HB d C @ @ HB d C  3HB d C 3HB d C 3HB d C %`B d 0 ? HB d C H d 0޽h ? 80___PPT10.=쨕0  P (  x  <A 6?? 6H  0޽h ? 80___PPT10.> -0 !x(  xx x <A 3??0 3 x c $Lz`` z M 1200 828 765 624$NP<H x 0޽h ? 80___PPT10.>0ωt2 0 11`Iv1(  x  c $\ 01 ?  v`B @ 01 ?``v`B B 01 ? |`B E 01 ? `B F 01 ? v \`B G 01 ?``B J 01 ?`v`\`B L 01 ? \ U `B U 01 ?`\`U `B V 01 ? U ; `B Z 01 ?`U `; `B \ 01 ? ; ! `B d 01 ?`; `! `B f 01 ? !  `B n 01 ?`! ` `B p 01 ?   `B x 01 ?` ` `B z 01 ?   `B  01 ?` ` `B  01 ?  `B  01 ?` ``B  01 ?  `B  01 ?```B  01 ?| `B  01 ? `B  01 ?`H  0޽h ? 33___PPT10i.p+k+D=' {= @B +- 0 ,,pBP,(  x  c ${P  { +  @  #"6* @@@@@@@@@@ {  BH{? @ g 56% reduction(  " @`  B? @ R  @`  B ?4 @ R  @`  B? 4@ R  @`  B{?   R  @`   BH&?   R  @`   BP(?  R  @`   B9?4  R  @`   B:? 4  R  @`   BK?   V   @`  BpM?  R  @`  B ^?  V   @`  Btf?@   R  @`  B$o? @   R  @`  Bq? @  R  @`  B?4@  R  @`  B?@ 4  R  @`  BD? @  `3.32*(" @`  B? @  l505 8.43*(" @`  BP?  @  R  @`  Bı?4 @  _1.9*(" @`  B?4@  o1764 29.4*(" @`  Bł?  `4.35*(" @`  B<?  j953 15.89*(" @`  B؂?   R  @`  B?4  `0.92*(" @`  B?4 o1560 26.0*(" @`  B?   o mg/dl( " @`   B?   R  @` ! B ?  t mg/dl( " @` " B4?@  _tyr*(" @` # B? @ _phe*(" @` $ B(? @  R  @` % B2?4@  _tyr*(" @` & B#?@4 _phe*(" @` ' BF?  @ bNeoPhe*(" @` ( BA?  @ R  @` ) BY? @ cControl*(" @``B * 01 ? `B 8 01 ?@`B : 01 ?  @`B < 01 ?@4@`B @ 01 ?  `B A 01 ?@`B B 01 ?  `B E 01 ? @ `B G 01 ?`B P 01 ?  `B Q 01 ?`B U 01 ?  `B W 01 ?@ `B _ 01 ?  @ `B a 01 ?@ `B i 01 ? @  `B k 01 ? `B t 01 ?   `B u 01 ? `B y 01 ?   `B { 01 ? @`B  01 ?  @`B  01 ?4@ @`B  01 ? @ @`B  01 ? @ @H  0޽h ? 33___PPT10i.p+k+D=' = @B +6 0  <(  ~  s *P   ~  s *D  B  s *޽h ? 3380___PPT10.Tb6 0  <(  ~  s *`P   ~  s *8  B  s *޽h ? 3380___PPT10.Tb 0 tl  (  x  c $t    0 HA &?p &   0\}0` VPaired t-test: p=0.001$0 2B  s *޽h ? ̙33 0 tl  (  x  c $d    0 HA '?*9 '   0` VPaired t-test: p=0.006$0 2B  s *޽h ? ̙33$ 0  $(  r  S HP   r  S   H  0޽h ? 80___PPT10.Mp00  0(  x  c $̱Pp  x  c $(   H  0޽h ? 80___PPT10.Vx< \TUy3̰0.hȾ( n駸 00P.Y"&bjߗZ_j▚kZjX.dXjnwνͼY4_7{s={y8tнzٻ!VDAiJ ҋ[WW G_t#]/ɅHw2<2z*fy}[O^ǵUI9nS}G=5J`=KFzi-jƪ#NEZWHnTBԈM RHAj 搼!@Aj%VZCR[*!~b]Υ$`ai tx0{P^_}kHr0^)S[d@Izx=ߺtIOp.D8W??7 _mBz>4-> +S8oJ\ ]X%g!Gth]HMڵ&[AmSlh[;]9UN-!lM{S"[peFnC^~\w9:RDe/2Qk2 c1JeYl>bS D׃cxŊ}lEⓄՏد96;i} Y&ezSzwge:ʐfPql'pDؼ=D't| b6)*vY(&KJ 70QLC!HDbVZ^n~nQ}B!Fщyvpycb3qjJu(|L hmwlްQC]5+##-@K:DkqՈ3:\4>8lG¸Tr+YI\6j*B'ml%09acp^O3%;&G==fPYk2yy+9+=J-Ԩ*TJ~=E%] z*H:8*y9w̻VsGm_nEuÑA|0xṮPҩ+ li 7KkKW) :tݣ=KKϐ[h+l-[o*h_ǥ?ofC҇Z"mnFdY#V[0XV`! _'q_SK-iip ~H*$!IGKfmhd,cbUDvi3Sކ؊ZVJU:sj p߰pp\ׯd{9X5ߒ9"|/ms" 4oX@s" iN)f*NUl =p| Ocd9ter' u#[a /_djlLU{C3[P狞ڭPT~[MYQ+P3/;;.(O##Y"ab.GQGFayTyˣD]X4#X`=J|ay)Gp1C@xLpx40Ňx F L1+ǠcAl䗸@F9RJx 0 \zcV. %b' 3茹:װJɨKץ :X4ua6r`a1_ ,OCF/8fliY8M4j~}h 7r]x(uFhI`3W-.Φ@b*{|+ls 0v [LZ8Έa.2ԚfGJP? s5jmV)†XABNW qǦn4W5>!##MUvrgޙi*"^'tM:l[}pImq<IɂmTP;]N&Åbn8v0:35qyPBVE6+[&B+bc@ztډ t^)@ @@0Ө$ iDLNKwnfê)Ergt ̑-."Xu40V:qSӖ萂ւ}NSm(~9N* E " Sj8u7== KWXrbY4vQŋ D15Z&e,6!CD!p}x ?O OC#gր_buw k]o-:5m7 5 [bST8-׃`Ѳ[Pe|Jmm`ÁQj‰T#&2zJ٩  9آ =RZPXyl\!y=qv]\tjs-*s]aŃtpI&1@>䐑$`0Aժ%0MPEEE"?OjUUU Y5kG:][SNj)ZGS&ސ+!]7OAzg+{9v2hQktĞ^)QCICJY:. b)!-+2AiT3oa\2:)B8S=[Ax^̢"(TMECVAַmDY.g[AV%:=;J=Q'Bu{:OѺ Y}O )2&`K< *VHJ%~$D$-S 4lzK28$*ܶqؿs83Ak].m8Sk+}&~_nl;O|qc=,{kE͒jsW>UM:gbVϞ9ctvO?35kKrK+xcV ?r仇긖 =g\7|fgj7G@&^qъ:@侇XbWZ bGsu-6?옣%d4j{h,=왣%fg{h2L왣1ӕYnhm[nTٖGcGb۵Rhi);6Y|t"ċ;Iv~@'ݹMݴa];8z C1HLTDN:_J %S&-=e'gmN0͝t/+I%>qR$('N=H7FSF#N\>wG-^s_QpAnjtҁM}^]ЭMM[>gUg>!cT%c픿 7Xl4( kU& Fxzlm/Np_^<8Ϧޚq S÷~bJ!#7|6xMo*nL񻵳(ŁY_l}&m~ɻܓÞtlVGWd;;͊iӆf {7 ai#|~teF5;LsAA%A1 ߚql߸$v{՟8= 7rnV˞υXTӱmsViѷ4kO]}Y]CejoH|:ԯyu x˂ߋ^'>!$--p. ԵQ5.fjj#(/9w CT=>uߛvڮh#X:cRMf?:~B2^}OG0wdNNn5/d)D)Gƾ}素 oW YF k1IYd[GRkmo: S/U*yx|׊pIow*]2b^J&^5(q).*V\/QyMr E qdfXJ:R a:攉8-pZZUArPtfs͔Q ~kPH"}( g і1w/hȂ+V6RGUT79OH8]㡓E9˦k7CGdKDK]7gH5~x= pUug? 1_+ғ q Dd@O@H$ ʴOۃ?ivL6MęxR$xbL;Sᑒ:il^9><=}f={vٳ{R|kg \p%&B3J"ywC-ЍЅa/ 8Y!ciÇd6}}U1v/ {3MMx0t)˦N2.`-z`3Ұ;m ccW,~w F94G_}X~1%藢 }%/C_>}-:/GߎWCwҍO:Z_P&㣰YcMitS}:ar1@-D_p_/A_~*OLG?kzwX<e 0<~\G6C' >ɩR~#0 }Pٻ9On8m\ҾNd2''Yi]Tֺ)=Fv7-ljth!{^6HuۄK^NzTx9#[$7\yK/a߽kBBB)ߨx>{+= {s /B~IguўѮpw[1PRAnT[²v57Gh G׶ck(P5{{Q>nԥLcRH0z׿oy@4Cu_%dʒѰ-:vF^IXs뾖~6ko<\R>ɣ޽8ȝ]ۚ6\nT(S_ns{oF^]w WjʄuHY]ޣx15)=MhKN`Nn;v&WšQ^ej+WWNZrafU5mm+8s*W}#ѥYNhHL5wA%b2Є9'8և5\ǖlz#wx=pSbE,k^v73Wa{w? Byue`&>;gϊ3ϋW(޿OY#'Q׆р:Vj0$ԍ$ j_w$疹g㬣_1oyU;}|B=}Ql[nPPed g)6Ut9,_[V U: έ߁U+a](Xhg䨱1I=&&enFI5Ϫ3oa0PB_ .^8w\N4i),iA0jn\ c^|B 8,y.@*a*ΐbtP*@񸎥*J9HXVK`=`}$&i,ExX50)N Q=]"wN?"򿏊+ˆ}yA5{1mwsF/aΊȠF$pwR׺o^ö=Qz?̿_ 9pfXPꦝ+sԏ^%EgO(d7];P"PǮ_HH*BN"D< u-@6!˹v˹@=SCD50 I'wX;nül\ L\w1NŸ~CA5: |hPa7^H7DZ'ɲd-VRdA]0 "ގءU~;6CyGv%p _qUJ5"-ˈD 0{")P sCSUM披VcDVXL:44dqlzRgS3w*BAZuȷS᳘wE9:#ƜRU9djfqx!-MĢ@Ѓ7|Gj'qM7ٱZt0{ø4)Fh6h!BSZ! Dy5 Ū" X{XhEF;\:']m=A$/% ilC$S?!7>+yWaA$ƭ5zoUyHvz>ٲ? RdXh^yGyK>7.sKW#;o7qM`+] x- Wf ou׷۬IJy0!G `~ӵB$5?i:3a,홐δ=j_С-jƎuOUxrx~.?QHl:ZW=aBx(7PuB#Ʃw %Yux$9 Cxu zHL/opA% LSWrB=ɿ[m [;ssܼ{ފ}"o6+,.l-;j5m/r׭-ޖuїږ]SiaN"|hPIV݋a+;Nk2R-&b>K;߅a4/ϘF%7޴tZ,O\v[~koo!&Ӌ]ȿ/'#aHg/zc.j^vؼwwqZffg[w ( EȍH7=?#%.yl/r Uًa.̿9}ƸkCy|RcHѻG~#E/>*1sA2{Hp ܃J.#E =}w+nwK="FG&]-yV5J`L4` X0`MKoL3{;J Zs!iH&Eg6h8/qMivYI#lnhdˤӬ6cNt3vЀ4`À5&fz0<ɾ6+GUlPM5;eMf@6=x+'~)Yt֐|6ns]1_HOUQ(V44 .Mn1<ʬ/ <-rS[fђtSIҟb*8QE#bqJx 9<j)JG)`>PsHۜN'᨝̹?Hx;=ݠGw^o%_7R~=nR:qxbR0r4WOi?Ҫ#|޸| M_RH!'QC3?\2d8#)d\/ #H0.b04.{X^qdc' hoݛޯ$kٗHm"?r\x=kpu~ӃB< #bK.1`H G\3X┎IRD-@;5mjwڝwu&3N0N=?&|=~zXػ={ιw{I;^ e`õTa=]KR1:6;հz|°T(6'EC.fރg|*?w~ʉy$bے Wa{ q<3Hgxې!؇Ϩ S (>&Ex/cbL%J1a rL@4LU>L1݈i25gc4\L0tbZfL`ZLu15`j$FGh g_ Zs\ySϾlF\LRPzG$gfikJ9S0VCUi -\%<vFz4GÖi2 s4Ѱ+`W@.h ;a'4lmհFVP:m-^"IR ʕwZL^eJ[ʞ'OhP3vFz4GÖi2 s4Ѱ+ a4섆аUk| suUe ײ.1W3mvz˦|cEYj[cF38-!|^8>T"5{}:kcjٳPψf~~6<]^a5QQXf&9ނ8Iuqձk$#cQ=|ʓHk2- 9Q{P#GW0h6#51 ΧdI7|hXI.j{|v㇚FE1SȎ&Þ@1t$ShtXzo{fF5gGKqXzo|4eh4Uc~_̚9}k_1a;&ST~>ߧܫW^׾ڧLXzW pwQט}~iҧT~bm`#{& .×zr|f#{f/PCG߱fh~߬m.A+,:}.z͌%ꨆ{4uxf+aagATV!p;LgRj̙SW[WkZmV;%CU?*a@qz?T=hdQu1y˂VlQ@oy]?E?o?l"?o+.^'! nKkF4*Q6S;g-JZ"J5BffF,45sH]޺ssl,_ܵw7S 7ܤ)Mh.5}&jYܹ@2V5nnDlϋX"ˏf\%7Z5T!0} ^o|믋kV-3F<Ƣ-4=s}7kS_{]TWa{cw 8%dF݃000FL\gmD B M\Ҩ VQ tYmP6R095 uw.T׺ ~M .GOz%&6r)vWrpmrM>&@.vPc]h`W B]*@+Q&RBAmdt:9D}XطqI?NBҠ62(C؎b).~]c]k;e-1O ?_Gi|A6Pjo\nI{ss];(w)mxT6+v> `X/ihd0lX\8?]Ɖ0"3~r|ZgR`:E.D{"ubɪG6}ACZ`[W)QNXρhߛ8Xt-% jZ#EvsyI5jxmǦeǐ ӜrFh4DJr*I] ҉0?b(/fkPVNn&jm RؼOէi w+ x[tq#כu E$'E!,Ea)qE(',Ҥ}H4E+r&N(⏹H3Ddi4Y8IO:^ݐ$(E5X;r^ f^C @~,ԗ.dpӋQ+M Kyg"?7'e.aWȁ|vC-}#xE]N؆\ 4imZ痱@{}b_JDs0I>Ktf"E9|' IFҳY΢ cm6AS -|xDWXZZ7X紓ZFyGLXig^ǍM88?gkx?>@HEwr&C8S7ΎB[%B39&ڦFI`8lZt*! U8I S0b$± VlqLiO`10%Bh&-3A[I\,^kz=4m\njk|FϪ,5S_ykLoc3H0Z]a+7jBbI!8bk,+ъ YKEɄgIx׃:BjCgľzَuo3bzVSsG`}lGl9X99nfsq!sc`[,98msէ6puP^PO9\.×7zo]!cِ;l~2K Z}XހzF~7O钚s]в&ml (6KM·mN=~rk"KQÍN#x֚mF;k"_Fݾ}_F-%~×=@U嵨嵌G51M`h;5)51 ]=MsML=>QFn>QOFu_Uune{`ǡO4Vzw'Gm|.4$g}6NIC>iñ$P%%->xjx)[eo 4sXiYLw >i֝K:YOC9?0Uˑ9TJz9nv'|JXiB+ipVo| R6CJMҠ=㩩l\aj݃~>i=N{ocU-ўs7iN*nʪ2H^X]*` [LZ]U_j ? m"6^ \'gx/7Ϧ]UT}'~VZh BCimwٵJTzןѯ?u<>ϬƣC][ga9mmؖh%:2ժ{}3V&4ԃ.бLףLB ("`3P^sG SG]%հ'jw|πўI>iD%ly~-+YHESCI/+1џiD,D|%@GAE)K΂_~ L|HP)wY#K]8wn7W/g@;6bf:*t𝵺 Tm& `+/(Q^_k"jxn$RXM&3!`tCb\SIrf&w6z 1k H;\tA60_>ltzKŸBqWq 4-t%Zݭg4Wx'a{vUe?NARh7. "_lV|c pYo00Ư!t,o4=q x~P;Ze.S-6hP?60jh~94~;4Hפ0< uD REO""WV4TQZW 쏟j  .sdWв JȡRRXZ h Q.|gg7 iG`Y`͟qÇiCcU7 &\ OuxWSL+|05ݑ"D ̤B)jM%7ܑ.+t!D2.ұ1AZh6xKxfk8i$RyLJEƥ^\V$H"d;Fw4 oɌw y)7F={ d=Ǘ{=' _e=ח{=7 ~<_$sLf}p?q/^op/H=ow7’y<.J}\5$^5ANȵS[Z< ڷLkM\G+ޟqS"mo9fړ8Ysl%wTYH">`.Ot3&l{5$6 (™ /3 ]a9KT 0LY.,9%p^v?Nkqk"^X#~s/gƵ9Wjz,5rh`ocHp: -Ew1|1 -)؞~Y./ƻEf]WW2?i%N`,F/J+WvKv,iݳm/d6ѠJ;_e$R'IO=wH-C/TjPtswN"IU;L>sI6%z>g#1l#`4lmְr +װK`@5lPÎjQ Ұ. +0qIiƘ+RNFOpyaM&edd1pK|1 vLÎif ۬aVa1 6avTÎjXuiXi(ODvKFV6zbƋ>R8>nI?\4,}_w⤠4V ƃ Mx|4γ@SgPt [3pmb.9)w6[HC%ar~?G5kQ4hg8~fZa8ر>9wUQPי'0ng-U݉+zu|4qb5{M9,A6ns&=i{D)3gHQ`/jYZۊVKxPM6&"{Dy㍮[*vxfii3G#y6їВj8\EDXbh3> l@_i $LgV]}ń%ki"ܸ 'ȧ @}קR +j_)O1Awʵ1ז뫘G^D/(ژe~՝I-%kSc0!+3-L>}}I= lPi6Q@l"h;iXk]J>?^{ g9pIw{ϡCM} *(ɚ؋k@KxFy%A8=h2TWUUjNoUMfY䭙j/ NpkOuls[1ٲeeٗpES LdGhZBHhpa\wGInK1uhCބIw 1j"MSSΩ%O}TO}o!C\mohKRg%13'?ww :i# JޯÞuZ-&-z/~9Uȷ!>!v@/0b6҃(=7;ʟb)(1Vclt角I,w^[i=욒Ʊ G˽VKf|%WWΨZ{C?ˁuٰ f)Xf>[n-W챜wA̭yN'獝$ȚDYXvQˑVRo*|*2|Xb|l|T2b`"m/⭊~*hN__OV@yBޯL[\[s KlWӮL>qsw,Q1'#ǕA@j &AM\{Ww~'6-fܭh9&QWlS8o ||g[qcXK<1ש&X&mu+Zq"+>9WNJ^~kwmZR<]LW5V[*QO=Y [nhs.+gI+` 0bxmpU}䑏$Ґ*#G'a"!/} N+OEЪЩN;v,ԩ_5XZGW:`;;:Vx=%$/mf={9g?N>ȡ ˭Nr g ;ŬX֝Un#LX=F`uc9_c̾YnŅv5>MMx0SD` X^؀}q4'|TML8 ۘ&. g.%r~U'ƙN*? aaX"<_~!J_A_Yy3Vw:MI dpS#Y9U"X,,Sg2dv=G~S}Zar0>WG_lX}OLG_guhDkg ?._ \[ }Sv_d8AGGƩhڷI~ YFZ$+:?@vΚ{k26G%VCBCD|i簏7TyD q{|X#v6#|Jo^R}K>ůwUS@+~S7Cڗm Fwz69jD@V$__LMPuN ;.7|C+礄.Qߧ1 'GNN8(pX@9]H D**~@J9٠TO)J9!5wj(q ècb= mdw^˽-EX_y4HY#z(Q ?GCKbH &b_Z݉vmG5K:#48#"eP#Z bWZz雗,u۹>`8Xv(Io^ iX/ߑ't.^{jdT%U)UubXST aXNr:b@USi ^@T2atL5C5U MIpm)و$/kr|U)^隅4L kr^S{CҾ29i5w3Xd7&g?=&HkGhr j{iXKa"n{qjM rrȐjȉ'm7C:cws/!tO!sG~D;[HK™yvS]&$2__%DK Ӷ[==[ӽ[C89SuB< E*m8ϵ[׳4{ǒ.eve9|[=ifӹ \Ajչ &8ܫ yjձt?aˉ 軎3;i$"I`ڦ-Xwԝt{u#_@2`E>1C]x-VΣfdyh.A22c1)KqYyξ8m5˜w쟍GJ1ZXU_3 uSh]v('z0?#>,vy'zA.;EO?v}=)zR?8sCdž{=|)SDG;}Vwwe)#kr<;8&gGyd+nܮsB AGJL 5O{QEGTJ WS X^/VXY _ "kDm@t=*s ][w  |P\P(<oE"Y 21Oh+'0 `h   ( 4@H\Future Role of Large Neutral Amino Acids in the Transport of Phenylalanine into the Brain UTMB UTMBOlya107Microsoft PowerPoint@K@Z@0H%nGdg  )0  y--$xx--'@Times New Roman-. 02 NeoPhe in the Treatment of ."SystemX-@Times New Roman-. 2 ".Phenylketonurias.-@Times New Roman-. *2 5*New Formulation of LNAA.-@Times New Roman-.  2 L,2s.-@Times New Roman-.  2 J0nd.-@Times New Roman-. 2 L8Ukraine Congress.-@Times New Roman-. %2 X,On Clinical Genetics.-@Times New Roman-. 2 b> October 2005.-՜.+,0    oOn-screen Showi)! &Times New RomanArialDefault DesignMicrosoft Excel ChartMicrosoft Graph ChartDNeoPhe in the Treatment of Phenylketonuria New Formulation of LNAAUSA Reuben Matalon, M.D., Ph.D. Kim Matalon Russia Peter Novikov Denmark Jytte Bieber Nielsen Leah Brammer Ukraine Elena Grechanina!Large Neutral Amino Acids (LNAA)Transport of LNAA to the BrainAndersen AE, Avinsl !Tyrosine in The Treatment of PKUTyrosine in Treatment of PKUTryptophan in Treated PKULNAA Supplementation in PKU PreKUnil Composition per Tablet!Km (app) – Km (1 + ∑[aa]/Km] Slide 12Neo Phe.LNAA Transport in Intestinal Mucosa Km mmol/L1Hidalgo Biochem Biophys. Acta 1008: 5-30a (1990)QPKU Mice on NeoPhe Control phe mg/dl NeoPhe Slide 17Denmark LNAA STUDYDenmark LNAA STUDY Russia LNAA STUDY Russia LNAA Study USA LNAA STUDYUSA LNAA STUDY Slide 24 Slide 25<US Blood Phe and Tyr NeoPhe Patient K 1 Week µmol/L (mg)/US Blood Phe and Tyr NeoPhe Patient G 1 Week NeoPhe 0.5 g/kg in PKU Subjects NeoPhe 1.0 g/kg in PKU SubjectsEFigure 1. Blood Phe Response to 0.5g/kg NeoPhe in Patients with PKUFFigure 2. Blood Phe Response to 1.0 g/kg NeoPhe in Patients with PKU CONCLUSIONSAcknowledgement  Fonts UsedDesign TemplateEmbedded OLE Servers Slide Titles!_2OlyaOlya  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root EntrydO)Pictures6Current UserSummaryInformation(PowerPoint Document(3DocumentSummaryInformation8